ADO

Across TCGA pan-cancer cohorts, ADO mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADO data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ADO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADO expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where ADO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.361	0.895	.007	23	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	6	view →
GBM	OS	Median	All	0.680	0.846	.044	1	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADO–HNSC (DFS)

Open the HNSC breakdown →